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Background
The insulin-like growth factor-I (IGF-I) receptor is a mem-
ber of a large family of transmembrane signal transducing
molecules. The IGF system is composed of IGF ligands,
receptors, and binding proteins. These system compo-
nents form a highly regulated network of interactions
both among themselves and between other biologic sig-
nalling pathways [1,2].
There are two characterised ligands, IGF-I and IGF-II
whose activities are mainly mediated by type I and II
receptors [1,3]. IGF-1R is necessary for the normal pro-
gression through the cell cycle and for normal growth and
development [4,5].
The principal pathways for transduction of the IGF signal
are mitogen-activated protein kinase and phosphatidyli-
nositol 3'-kinase [6,7]. After ligand-dependent receptor
autophosphorylation, the IGF-IR phosphorylates a series
of adaptor proteins, including insulin receptor substrate-
1, to activate intracellular signalling cascades [7]. The pro-
tein kinase pathway is responsible for the mitogenic sig-
nal observed after IGF stimulation but may also be
accountable for cell survival in cells over expressing the
IGF-1R [8]. The IGF system has been implicated in pro-
moting mitogenic, metastatic, and antiapoptotic pheno-
types in breast cancer. As a consequence of the ability of
IGF to promote tumorigenesis, pharmacologic interven-
tions targeting the IGF system are being devised [9-11]. It
is believed that IGF-1 can affect breast cells through endo-
crine, autocrine, and paracrine mechanisms [12-14].
We have recently reported using RT-PCR that IGF-1 is
lower in breast cancer tissue than in adjacent non-cancer-
ous breast tissue (ANCT) thus supporting the paracrine
hypothesis [15]. The same study demonstrated no signifi-
cant difference in the expression of IGF-1R between breast
cancer and ANCT, neither was there any significant corre-
lation between PCR and immunohistochemistry (IHC)
expressions of IGF-1R [15].
This aim of our study is to evaluate the relationship
between mRNA expression levels of IGF-1 and various
clinicopathological parameters.
Methods
Specimens
A total of 31 patients (n = 31) with diagnosis of operable
breast cancer were randomly selected. Local protocols
were followed regarding ethical approval and patients'
consent. A specimen of tumour and another specimen of
ANCT were obtained from each patient. They were frozen
in liquid nitrogen within 30 minutes of excision and
stored at -70°C until use.
RNA extraction
Total cellular RNA was extracted from cancerous tissue
and ANCT using Total RNA Isolation Reagent (Advanced
Biotechnologies) according to manufacturer's protocol.
Approximately 10 mg of cancerous tissue was homoge-
nized. A larger amount of ANCT (20 – 50 mg) was used as
high fat content made it difficult to obtain a sufficient
RNA concentration for analysis. Quantification of RNA
following treatment with DNase was carried out in tripli-
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cate using Ribogreen reagent (Molecular Probes Europe
BV, Leiden, Netherlands) according to manufacturer's
protocol.
RT-PCR
Taqman RT-PCR was carried out on each sample using the
SYBR Green PCR Mastermix (Applied Biosystems, War-
rington, UK) and the ABI PRISM 7700 Sequence Detector
(Perkin Elmer Applied Biosystems, Warrington, UK)
according to manufacturer's protocol. The RNA extraction
and the preparation of the RT-PCR mix were carried out in
different rooms. Preparation of the RT-PCR mix was car-
ried out in an extraction hood.
The sequences for the forward and reverse oligonucleotide
primers and probes were designed using Primer Express
Software (PE-Applied Biosystems, Warrington, UK) and
were intron spanned to prevent amplification of genomic
DNA. The oligonucleotide sequences of these primers and
probes are given in table 1.
The conditions for the reverse transcription were 50°C for
2 min, 60°C for 10 min and 92°C for 5 min. The
polymerase chain reaction step was carried out for 50
cycles for 20 sec at 92°C and 25 sec at 62°C. For negative
controls, RNase-free water was used in the RT-PCR instead
of RNA. For positive controls, 18S ribosomal mRNA was
used. The relative levels of IGF-1 and IGF-1 R mRNA
expression were calculated by comparing their readings
(arbitrary units) to the readings of a housekeeping gene
(18S ribosomal mRNA). The association between the rel-
ative levels of IGF-1 and IGF-1R mRNA and clinicopatho-
logical parameters was examined using statistical analysis
of variance. The clinicopathological parameters included
patients' age, tumour size, grade vascular invasion, estro-
gen receptor (ER) status, lymph node status, and associ-
ated DCIS.
Results
All 31 patients had their operations performed in the
period between January 1997 to December 1998 and
underwent either a mastectomy or a wide local excision
together with lymph node clearance or sampling. The
median age was 69 and 7 patients were below the age of
50. Six patients were pre-menopausal. All samples con-
tained invasive ductal carcinoma and 14 of these also con-
tained ductal carcinoma in-situ (DCIS). 18 cases were
positive for estrogen receptor (ER) immunostaining. His-
tological grading of cancerous tissue revealed 3 cases of
grade 1, 10 cases of grade 2 and 17 cases of grade 3. The
histology grade of one case could not be determined.
All 31 specimens had detectable levels of mRNA for both
IGF-1 and IGF-1R. The median values of relative expres-
sion of IGF-1 mRNA were 0.469 (0.281–0.711) 0.762
(0.338–0.874) in tumour and ANCT respectively (p =
0.0002).
The IGF-1 receptor values were 0.118 (0.0763–0.1685) in
tumour specimens and 0.0944 (0.0356–0.1242) in
ANCT. The difference was not statistically significant indi-
cating a more universal expression.
We observed a significant association between IGF-1
mRNA expression and lymph node status (0, 1–3, >3 pos-
itive lymph nodes, p = 0.0032).
Table 1: Sequence of Taqman primers and probes for RT-PCR
Name of gene Forward Primers Reverse Primers Probe
IGF-1 5-CTT CAG TTC GTG
TGT GGA GAC AG-3
5-CGC CCT CCG
ACT GCT G-3
5-TTT TAT TTC AAC AAG
CCC ACA GGT ATG GC-3
IGF-1R 5-CTC CTG TTT CTC
TCC GCC G-3
5-ATA GTC GTT GCG
GAT GTC GAT-3
5-TGG CCC GCA GAT
TTC TCC ACT CGT-3
Table 2: Shows a summary of p-values of the associations between IGF-1 and IGF-1R mRNA and clinicopathological parameters
Parameter ER DCIS Grade LN (1–3) LN +/- Age >60 Size >2 cm Vasc Inv
IGF-1R
Tumour 0.5498 0.8456 0.8789 0.8832 0.9412 0.3683 0.855 0.5717
Normal 0.342 0.9643 0.7442 0.1691 0.2676 0.9382 0.8713 0.4742
T: N 0.1231 0.5249 0.6828 0.0608 0.2204 0.2733 0.2003 0.5073
IGF-1
Tumour 0.544 0.2966 0.1084 0.0657 0.9384 0.115 0.7417 0.5879
Normal 0.8 0.1031 0.9513 0.0032 0.9144 0.1376 0.8699 0.4279
T: N 0.6857 0.107 0.1985 0.0288 0.1196 0.8906 0.8279 0.998Journal of Carcinogenesis 2006, 5:16 http://www.carcinogenesis.com/content/5/1/16
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There was no significant association between IGF-I mRNA
expression and patients' age (p = 0.3683), tumour size (p
= 0.855), grade (p = 0.8789), vascular invasion (p =
0.5717), ER status (p = 0.5498) or the presence of DCIS (p
= 0.8456).
There was no significant association between IGF-1R
mRNA expression and patients' age (p = 0.115), tumour
size (p = 0.7417), grade (p = 0.1084), vascular invasion (p
= 0.5879), ER status (p = 0.544), the presence of DCIS (p
= 0.2966), lymph node status (p = 0.9412) or tumour
stage (p = 0.0608–0.943). Table 2 shows the various p-val-
ues.
We observed an interesting significant association
between IGF-1R and the type of surgical procedure per-
formed (wide local excision/mastectomy) (p = 0.0288).
Table 3 shows the raw data.
Discussion
Previous data shows that the interaction of insulin-like
growth factors (IGFs) with the IGF-I receptor promotes
Table 3: Raw data
Age OP Grade Size mm DCIS/
grade
Vas. LN ER IGF-1 IGF-1R
53 WLE 3 25 No No 0/8 Neg 0.610 0.166
78 WLE 1 22 Y/Low No 1/15 Pos 0.724 0.189
88 Mast 3 110 No Yes Dif Neg 0.719 0.067
90 WLE 3 23 No No 0/13 Pos 1.037 0.036
83 Mast 3 70 No Yes 17/17 Pos 0.854 0.177
58 Mast 3 90 No Yes 6/13 Neg 0.403 0.169
54 Mast 2 32 Y/High ? 0/13 Pos 0.398 0.305
74 Mast 2 25 Y/High No 1/12 Pos 0.489 0.235
85 Mast 2 14 No NK 0/19 Neg 0.512 0.271
59 Mast 3 22 Y/High No 1/5 Neg 0.499 0.180
72 Mast 3 35 Y/High Yes 1/2 Neg 0.548 0.168
72 Mast 2 10 No No 0/15 Pos 0.605 -
78 Mast 3 40 No No 0/7 Neg 0.711 0.029
86 WLE 3 30 No No 0/1 Pos 0.785 0.126
66 Mast 1 25 Y/High No 0/11 Pos 0.186 0.076
77 WLE 3 30 Y/High No 0/13 Neg 0.261 0.059
46 WLE 3 25 No No 1/10 Neg 0.345 0.096
79 WLE 1 13 No Yes 0/1 Pos 0.328 0.211
46 WLE 3 38 No Yes 0/21 Neg 0.319 -
66 Mast 3 32 Y/NK Yes 2/17 Pos - 0.065
65 WLE 3 26 Y/High Yes 1/20 Neg 0.562 0.129
78 Mast 2 22 No No 0/12 Pos 0.546 0.352
45 WLE 2 20 No No 1/28 Pos 0.426 0.159
37 WLE 3 20 Y/High No 1/14 Neg 0.444 0.207
38 WLE 3 15 Y/High No 1/7 Pos 0.370 0.122
41 WLE 3 23 No Yes 6/7 Neg 0.158 0.074
74 WLE 3 36 No No 0/13 Pos 0.187 0.106
70 WLE 2 35 Y/NK Yes 5/18 Pos 0.178 0.114
62 WLE 2 26 Y/Inter Yes 3/13 Pos 0.155 0.126
82 WLE 1 12 No No 0/28 Pos 0.193 0.074
80 Mast 2 35 Y/Low Yes 1/12 Pos - -
Key: WLE: Wide Local Excision
Mast: Mastectomy
Vas.: Vascular invasion
LN: Positive lymph node
NK: Not Known
Pos: Positive, Neg: Negative
Y: Yes
ER: Estrogen receptor status
Dif: Diffuse
Inter: IntermediateJournal of Carcinogenesis 2006, 5:16 http://www.carcinogenesis.com/content/5/1/16
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cell proliferation, stimulates mitosis, combats apoptosis,
and induces the transformation of normal cells to cancer
cells [5,16-19].
IGFs seem to be freely available to the malignant epithe-
lial cells from both endocrine and paracrine sources.
However, the relative importance of endocrine produc-
tion in normal breast tissues remains to be defined.
Earlier studies looked into the association between IGF-1/
IGF-1R expression and clinicopathological features of
breast cancer with conflicting results. Pappa V et al found
no correlation between IGF1-R content and a variety of
tumor parameters (tumor size, lymph node involvement,
grade) and host characteristics (age, body mass index,
menopausal status) [20]. Other studies, although looked
at IGF-1 mRNA expression, failed to examine its relation
to other clinical parameters [12,21,22].
The level of IGF-I mRNA expression seems to correlate
with the nodal status, the best single prognostic indicator
in human breast cancer. There is an increasing body of evi-
dence that estrogen induces the expression of several
members of IGF family including IGF-I, IGF-1R, IGF-II
and IGF-2R [23-26]. The lack of correlation between ER
status and both IGF-I and IGF-1R could be explained on
the basis of the multiplicity of molecular markers influ-
enced by estrogen.
The lack of correlation between both IGF-I and IGF-1R
and patients' age, tumour size, grade, vascular invasion or
the presence of DCIS are in consistence with the findings
of Sancak et al [27] who found no association between the
serum level of IGF-I and these clinicopathological param-
eters. It is important to note that protein expression does
not always correlate with gene expression. The signifi-
cance of the association between IGF-1R and the type of
procedure performed is yet to be explained.
Our results should be interpreted with caution due to the
small sample size.
The significant correlation we observed between nodal
status and mRNA expression levels underscores the need
for further studies with long-term clinical outcome data to
validate the potential role of IGF-1 expression as a prog-
nostic marker.
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